Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanabenz in vanishing white matter extension study
NL-OMON60204Phase 2Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of guanabenz in leukoencephalopathy with vanishing white matter (VWM), sponsored by Amsterdam University Medical Center. Primary endpoint: Ambulation change over study period. Started Dec 2025; status: recruiting.
02
Drugs
guanabenz
03
Conditions
leukoencephalopathy with vanishing white matter (VWM)
Beyond the preview
Go deeper on NL-OMON60204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60204.